PKPaul Kleihues

Paul Kleihues

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul Kleihues has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The 2007 WHO classification of tumours of the central nervous system

    by David N. Louis, Hiroko Ohgaki, Otmar D. Wiestler, Webster K. Cavenee, Peter C. Burger, Anne Jouvet, Bernd W. Scheithauer, Paul Kleihues


  • Top Cited Papers
    Open Access

    The 2007 WHO Classification of Tumours of the Central Nervous System

    by David N. Louis, Hiroko Ohgaki, Otmar D. Wiestler, Webster K. Cavenee, Peter C. Burger, Anne Jouvet, Bernd W. Scheithauer, Paul Kleihues

    The fourth edition of the World Health Organization (WHO) classification of tumours of the central nervous system, published in 2007, lists several new entities, including angiocentric glioma, papillary glioneuronal tumour, rosette-forming glioneuronal tumour of the fourth ventricle, papillary tumour of the pineal region, pituicytoma and spindle cell oncocytoma of the adenohypophysis. Histological variants were added if there was evidence of a different age distribution, location, genetic profile or clinical behaviour; these included pilomyxoid astrocytoma, anaplastic medulloblastoma and medulloblastoma with extensive nodularity. The WHO grading scheme and the sections on genetic profiles were updated and the rhabdoid tumour predisposition syndrome was added to the list of familial tumour syndromes typically involving the nervous system. As in the previous, 2000 edition of the WHO ‘Blue Book’, the classification is accompanied by a concise commentary on clinico-pathological characteristics of each tumour type. The 2007 WHO classification is based on the consensus of an international Working Group of 25 pathologists and geneticists, as well as contributions from more than 70 international experts overall, and is presented as the standard for the definition of brain tumours to the clinical oncology and cancer research communities world-wide.


    • 1 November 2003
      • Vol. 12, 1241-7

    Endogenous deoxyribonucleic Acid (DNA) damage in human tissues: a comparison of ethenobases with aldehydic DNA lesions.

    by Alain Barbin, Hiroko Ohgaki, Jun Nakamura, Michael Kurrer, Paul Kleihues, James A Swenberg

    Two types of endogenous DNA lesions, ethenobases [1,N(6)-ethenoadenine (epsilonA), 3,N(4)-ethenocytosine (epsilonC)] and aldehydic DNA lesions (ADLs), were measured in several tissues (liver, lung, kidney, colon, colon mucosa, cerebellum, and gray and white matter of the cerebrum) obtained postmortem during autopsy examinations of 12 individuals (6 males, 6 females; ages, 58-87 years). Issues relating to changes in levels of DNA damage with disease and after death were addressed. The extent of DNA damage in autopsy samples was not associated with the length of the postmortem interval and was similar to levels observed in surgery samples, suggesting that endogenous, steady-state levels of etheno adducts and of ADLs are relatively stable during the hours immediately after death. In this limited series of samples, and with a few possible exceptions, the disease status before death was not associated with increased endogenous DNA damage in the affected tissue. DNA ethenobases were lowest in the cerebellum (median molar ratios: epsilonA/A = 1.0 x 10(-8); epsilonC/C = 1.9 x 10(-8)) and highest in the gray matter (epsilonA/A = 2.9 x 10(-8); epsilonC/C = 4.8 x 10(-8)) and white matter (epsilonA/A = 2.4 x 10(-8); epsilonC/C = 5.2 x 10(-8)) of the cerebrum. In other tissues, median values were 1.2-1.9 x 10(-8) for epsilonA/A and 2.0-3.3 x 10(-8) for epsilonC/C. There was a good correlation between the levels of epsilonA and epsilonC (r = 0.80, P < 0.0001). Levels of ADLs were similar in the liver, lung, kidney, and white matter of the cerebrum (median values: 5.7-7.9 ADLs/10(6) nucleotides), higher in the colon (11.3 x 10(-6)) and gray matter of the cerebrum (9.0 x 10(-6)) and lower in the cerebellum (3.7 x 10(-6)). There was no correlation between levels of ethenobases and amounts of ADLs (epsilonA versus ADLs: r = 0.12, P = 0.33; epsilonC versus ADLs: r = 0.024, P = 0.85). Although there was an interindividual variability in the extent of endogenous DNA damage (4-fold for epsilonA and epsilonC, 2-fold for ADLs), which may be determined, in part, by the capacity to repair DNA and may be related to the pathology or treatment of the patients, these results suggest that the cerebrum contains higher endogenous DNA damage than the other tissues. These data are in line with previous studies showing that brain tissues are more susceptible to oxidative stress and lipid peroxidation than other tissues.


    • 15 October 2003
      • Vol. 63  (20) , 6643-50

    Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

    by Magali Olivier, David E Goldgar, Nayanta Sodha, Hiroko Ohgaki, Paul Kleihues, Pierre Hainaut, Rosalind A Eeles

    A database has been created to collect information on families carrying a germ-line mutation in the TP53 gene and on families affected with Li-Fraumeni syndromes [Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like syndrome (LFL)]. Data from the published literature have been included. The database is available online at http://www.iarc.fr/p53, as part of the IARC TP53 Database. The analysis of the 265 families/individuals that have been included thus far has revealed several new findings. In classical LFS families with a germ-line TP53 mutation (83 families), the mean age of onset of breast cancer was significantly lower than in LFS families (16 families) without a TP53 mutation (34.6 versus 42.5 years; P = 0.0035). In individuals with a TP53 mutation, a correlation between the genotype and phenotype was found. Brain tumors were associated with missense TP53 mutations located in the DNA-binding loop that contact the minor groove of DNA (P = 0.01), whereas adrenal gland carcinomas were associated with missense mutations located in the loops opposing the protein-DNA contact surface (P = 0.003). Finally, mutations likely to result in a null phenotype (absence of the protein or loss of function) were associated with earlier onset brain tumors (P = 0.004). These observations have clinical implications for genetic testing and tumor surveillance in LFS/LFL families.


  • Methylation of the p73 gene in gliomas

    by Takao Watanabe, Huatao Huang, Mitsutoshi Nakamura, Jörg Wischhusen, Michael Weller, Paul Kleihues, Hiroko Ohgaki

    The p73 gene encodes a protein structurally and functionally homologous to TP53, and maps to chromosomal band 1p36.33, where loss of heterozygosity has been observed in up to 90% of oligodendrogliomas and in 10–25% of diffuse astrocytomas. We assessed the methylation status of the CpG islands in the promoter region of the p73 gene by methylation-specific PCR in 117 glioma biopsies. Methylation was detected in 5 out of 28 (18%) glioblastomas and in 4/26 (15%) anaplastic oligodendrogliomas (WHO grade III) but not in grade II oligodendrogliomas, low-grade diffuse astrocytomas (grade II), and anaplastic astrocytomas (grade III). To assess whether p73 methylation leads to loss of expression, we carried out reverse transcription-PCR and methylation-specific PCR in 10 glioblastoma cell lines. Two lines (U87MG and T98G) showed p73 methylation. U87MG had no unmethylated p73 (complete methylation), and showed loss of expression. T98G had methylated and unmethylated p73 (partial methylation), and retained p73 expression. A third cell line (LN-308) showed loss of p73 expression without p73 methylation. These results suggest that complete p73 methylation is associated with loss of expression, but that additional mechanisms may cause loss of p73 expression. Analysis of a polymorphic site in exon 2 further showed that p73 was mono-allelically expressed in 6 out of 7 primary gliomas with heterozygous GC/TA polymorphism.


    • 1 May 2002
      • Vol. 8  (5) , 1117-24

    Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.

    by Aurelia Peraud, Friedrich W Kreth, Otmar D Wiestler, Paul Kleihues, Hans-Jürgen Reulen

    The purpose of this study was to analyze retrospectively timing, frequency, and prognostic impact of TP53 mutations and P53 protein accumulation in supratentorial WHO grade II astrocytomas and oligoastrocytomas of adult patients. We included 159 consecutively treated patients (1991-1998), and each tumor was screened for TP53 mutations and P53 protein overexpression. Prognostic evaluation was performed with the multivariate proportional hazards model. TP53 mutations (P53 protein overexpression) were detected in 49% (47%) of all tumors with a preference for the gemistocytic subtype (P < 0.05). The TP53 status of the primary tumor was predictive for the status of the recurrent tumor, and tumor recurrence/progression was associated with an increase of P53 immunopositive cells in 68% of the investigated tumors. Univariately, gemistocytic subtype and presence of TP53 mutation (but not P53 accumulation) were unfavorable predictors for progression-free survival (P < 0.05); multivariately, only the gemistocytic subtype remained unfavorable influence (P = 0.04). No overall prognostic impact of the TP53 status on survival and time to malignancy was observed (P < 0.05). Five nongemistocytic tumors with a codon 175 TP53 mutation exhibited a significantly worse prognosis as compared with those with any other mutational sites (5-year progression-free survival: 0%; 5-year malignant transformation: 100%; P < 0.001). TP53 mutations are frequent and early events in the pathogenesis of WHO grade II astrocytomas/oligoastrocytomas, and most of the univariately detected overall prognostic impact of the TP53 status must be related to the influence of the gemistocytic subtype. In nongemistocytic astrocytomas, a hot spot codon 175 TP53 mutation indicates a worse prognosis in terms of time to progression and malignancy.


  • K-ras mutations are frequent in pulmonary squamous cell carcinomas but not in adenocarcinomas of WBN/Kob rats induced by N-nitrosobis(2-oxopropyl)amine

    by Hiroko Ohgaki, Fumio Furukawa, Michihito Takahashi, Paul Kleihues

    Pulmonary carcinomas induced by N-nitrosobis(2-oxopropyl) amine (BOP) in WBN/Kob rats were screened for point mutations in the K-ras protooncogene. Exons 1 and 2 were polymerase chain reaction amplified from paraffin-embedded sections, followed by direct DNA sequencing. G ↑ A transition mutations in the second base of codon 12 of the K-ras gene were found in 6/24 (25%) rat lung tumors induced by BOP. The incidence of point mutations was significantly higher (P < 0.005) in squamous cell carcinomas (5/7; 71%) than in adenocarcinomas (1/17; 6%), suggesting that the mutational activation of K-ras is associated with a differential growth advantage in these two histologically distinct types of lung tumors in rats. No mutations were found in codons 13, 61 or adjacent regions of these codons.